Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Reports Outline Medicinal Chemistry Study Results from Sanofi (Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum)

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:30pm CET

By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Medicinal Chemistry have been published. According to news reporting originating in Frankfurt, Germany, by NewsRx journalists, research stated, "The scientific advances being made across all disciplines are creating ever-increasing opportunities to enhance our knowledge of biological systems and how they relate to human disease. One of the central driving forces in discovering new medicines is medicinal chemistry, where the design and synthesis of novel compounds has led to multiple drugs."

The news reporters obtained a quote from the research from Sanofi, "Chemical biology, sitting at the interface of many disciplines, has now emerged as a major contributor to the understanding of biological systems and is becoming an integral part of drug discovery. Bringing chemistry and biology much closer and blurring the boundaries between disciplines is creating new opportunities to probe and understand biology; both disciplines play key roles and need to join forces and work together effectively to synergize their impact. The power of chemical biology will then reach its full potential and drive innovation, leading to the discovery of transformative medicines to treat patients."

According to the news reporters, the research concluded: "Advances in cancer biology and drug discovery highlight this potential."

For more information on this research see: Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. Cell Chemical Biology, 2017;24(9):1058-1065. Cell Chemical Biology can be contacted at: Cell Press, 50 Hampshire St, Floor 5, Cambridge, MA 02139, USA (see also Medicinal Chemistry).

Our news correspondents report that additional information may be obtained by contacting A.T. Plowright, Sanofi Aventis Deutschland GmbH, Integrated Drug Discovery, D-65926 Frankfurt, Germany. Additional authors for this research include C. Ottmann, M. Arkin, Y.P. Auberson, H. Timmerman and H. Waldmann.

Keywords for this news article include: Frankfurt, Germany, Europe, Medicinal Chemistry, Chemical Biology, Chemicals, Sanofi.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
02:25a SANOFI : Researchers from Sanofi Pasteur Describe Findings in Rabies Virus (A no..
02:12a REGENERON PHARMACEUTICALS : and Sanofi To Accelerate and Expand Investment for C..
01/18 SANOFI : EDITORIAL - Sober approach
01/18 SANOFI : NBI to submit initial result of probe on Dengvaxia mess
01/17 SANOFI : Palace welcomes P1.4-B refund for unused Dengvaxia
01/17 SANOFI : Duque insists on full refund of govt payment for Dengvaxia
01/17 SANOFI TAPS TRINETX TO UP EFFICIENCY : Were at a stage of true transformation
01/17 SANOFI : to retrieve remaining Dengvaxia stocks by Friday
01/17 SANOFI : to pay back Philippines after Dengue vaccine problems
More news
News from SeekingAlpha
01/17 NOVO NORDISK : Don't Spoil The Ablynx Acquisition
01/17 De-Risking Catalysts Aplenty - Cara Therapeutics
01/16 WALL STREET BREAKFAST : More Records In Store For Equities
01/14 CDC : Worst flu season in years
Financials (€)
Sales 2017 35 753 M
EBIT 2017 9 145 M
Net income 2017 8 056 M
Debt 2017 5 648 M
Yield 2017 4,15%
P/E ratio 2017 11,42
P/E ratio 2018 16,02
EV / Sales 2017 2,73x
EV / Sales 2018 2,69x
Capitalization 92 045 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 29
Average target price 83,9 €
Spread / Average Target 15%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI1.42%113 518
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287